Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSI526: sourced facts only. name: "Among the synthesized compounds, GSI526 emerged as a potent degrader, demonstrating efficient IRAK4 degradation in THP-1 cells with a DC₅₀ of 40.17 nM." [PMID:42097519]; target: "Among the synthesized compounds, GSI526 emerged as a potent degrader, demonstrating efficient IRAK4 degradation in THP-1 cells with a DC₅₀ of 40.17 nM." [PMID:42097519]; developer: "Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China." [PMID:42097519]; modality: "we designed and synthesized a novel proteolysis-targeting chimera (PROTAC) aimed at degrading IRAK4." [PMID:42097519]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GSI526.